B3(Fab)-streptavidin Tetramer Has Higher Binding Avidity than B3(scFv)-streptavidin Tetramer
- Authors
- Won, Jae Seon; Kang, Hye Won; Nam, Pil Won; Choe, Mu Hyeon
- Issue Date
- 20-5월-2009
- Publisher
- WILEY-V C H VERLAG GMBH
- Keywords
- Recombinant antibody; Refolding; Fab; Homo-tetramer; Antibody therapy
- Citation
- BULLETIN OF THE KOREAN CHEMICAL SOCIETY, v.30, no.5, pp.1101 - 1106
- Indexed
- SCIE
SCOPUS
KCI
- Journal Title
- BULLETIN OF THE KOREAN CHEMICAL SOCIETY
- Volume
- 30
- Number
- 5
- Start Page
- 1101
- End Page
- 1106
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/120037
- ISSN
- 0253-2964
- Abstract
- Multivalent and multi-specific antibodies can provide valuable tools for bio-medical research, diagnosis and therapy. In antigen-anti body interactions, the avidity of anti bodies depends on the affinity and the number of binding sites. As artificial multivalent antibody agents, single chain Fv-streptavidin fusion tetramer proteins (scFv-SA)(4) have been previously tested.(1,2) Although, the Fab domain is known to be more stable than scFv in animal models, (3,4) it has never been used to make a multivalent agent with a streptavidin fusion. In this study, we prepared tetra-valent (Fab-cSA)(4) by fusing Fab with core streptavidin (cSA). This molecule was made using inclusion body production, refolding and chromatography purification. Affinities of the Fab-cSA tetramer and a scFv-cSA tetramer to a cell surface antigen were compared by ELISA using biotin-HRP. The Fab-cSA tetramer showed higher binding avidity than the scFv-cSA tetramer. The higher binding avidity of the Fab-cSA tetramer demonstrates its potential as a therapeutic agent for target-specific antibody therapy.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Life Sciences and Biotechnology > Division of Life Sciences > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.